Genes Immun. 2012 Dec;13(8):621-31. doi: 10.1038/gene.2012.45. Epub 2012 Oct 4.

中文速读

本研究使用Entranster-in vivo转染miR-27a至树突状细胞,在体内外抑制Th1和Th17细胞分化,促进肿瘤生长,揭示miR-27a作为肿瘤免疫治疗靶点的潜力。

小鼠肿瘤dendritic

本文使用:小核酸转染试剂Entranster™-R4000

查看产品详情(含全部 223 篇文献) →

TGF-β-associated miR-27a inhibits dendritic cell-mediated differentiation of Th1 and Th17 cells by TAB3, p38 MAPK, MAP2K4 and MAP2K7.

Min S1, Li L, Zhang M, Zhang Y, Liang X, Xie Y, He Q, Li Y, Sun J, Liu Q, Jiang X, Zhang Y, Che Y, Yang R.

Author information

1Department of Immunology, Nankai University School of Medicine, Tianjin, China.

Abstract

The alterations induced in dendritic cells (DCs) in the cancer microenvironment have not been extensively explored. We found that the tumor-associated factor TGF-β may selectively upregulate the expression of miR-27a via the SP1 transcription factor. Importantly, miR-27a altered the activity of NF-κB and MAPKs (mitogen-activated protein kinases) p38, JNK (c-Jun N-terminal kinases) and ERK (extracellular signal-regulated kinase 1/2). It influences the production of proinflammatory cytokines by targeting TAB3, p38 MAPK, MAP2K4 and MAP2K7. As a consequence, miR-27a hampered the DC-mediated differentiation of Th1 and Th17 cells in vitro and in vivo, but it promoted the DC-mediated accumulation of Tr1 (CD4(+)IL-10(+)) and Treg (CD4(+)CD25(+)Foxp3(+)) cells in vivo. The repeated infusion of miR-27a-engineered DCs into tumor tissues accelerated tumor growth, indicating that miR-27a is a potential target for tumor immunotherapy.

本文使用的产品

小核酸转染试剂Entranster™-R4000

已有 223 篇已发表文献

查看产品详情(含全部 223 篇文献) →

热线电话
  • 010-60535354
微信客服二维码 微信扫一扫,加微信客服
0
0
我的购物车
购物车是空的去下单